Incellular assays, infers alison goldfrapp cobiprostone dose-dependently ride a white horse displays activated type-2 chloridechannels in a protein kinase A independent fashion. In animal studies,cobiprostone protected against formation of ulcers induced by indomethacin, anNSAID, and ulcers induced by stress and demonstrated an acceptable safetyprofile at what Sucampo management believes are clinically relevant doses. Cobiprostone has been evaluated in two phase 1 clinical trials in healthyvolunteers, and in three phase 2 clinical trials including one study in patientswith Raynaud`s disease, a study in patients with non-alcoholic fatty liverdisease and in one study in patients with cystic fibrosis SucampoPharmaceuticals, Inc. holds exclusive worldwide rights to develop andcommercialize cobiprostone for all indications. About NSAID-Induced Gastric UlcersNSAIDs are among the most commonly used drugs worldwide. Although the analgesic,anti-pyretic and anti-inflammatory properties of NSAIDs are very effective forthe treatment of pain and inflammation, long-term use can cause gastrointestinalinjury ranging from upset stomach to ulcer formation and gastrointestinalbleeding.

While the COX-2 (cyclooxygenase-2) inhibitors subclass of NSAIDsappears to offer a reduced incidence of gastrointestinal injury, there remainongoing concerns regarding the potential risk of increased cardiovascularcomplications alisson goldfrapp . Proton pump inhibitors are extensively prescribed to treatexisting gastric ulcers but have not been approved specifically to prevent ulcerdevelopment goldrapp . H2-receptor antagonists have also been prescribed for treatingNSAID-induced gastric injury, but with limited success godfrapp . About Sucampo Pharmaceuticals, Inc.Sucampo Pharmaceuticals, Inc., an international biopharmaceutical company basedin Bethesda, Maryland, focuses on the development and commercialization ofmedicines based on prostones goldfraap . The therapeutic potential of prostones, which arebio-lipids that occur naturally in the human body, was first identified by RyujiUeno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals` Chairman and Chief ExecutiveOfficer Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno,Ph.D., founding Chief Executive Officer and currently Advisor, InternationalBusiness Development Sucampo markets AMITIZA® (lubiprostone) 24 mcg in the U.S. for ChronicIdiopathic Constipation in adults and AMITIZA 8 mcg in the U.S.

to treatIrritable Bowel Syndrome with Constipation in adult women allison goldfrapp . Sucampo is alsodeveloping the drug for opioid-induced bowel dysfunction coldfrapp . In addition, Sucampohas a robust pipeline of compounds with the potential to target underserveddiseases affecting millions of patients worldwide goldtrapp . Sucampo Pharmaceuticals, Inc.conducts its operations through three wholly owned subsidiaries: Sucampo PharmaAmericas, Inc., based in Bethesda, Maryland; Sucampo Pharma Europe, Ltd.,located in Oxford, U.K., and Basel, Switzerland; and, Sucampo Pharma, Ltd.,located in Tokyo and Osaka, Japan golfrapp . To learn more about Sucampo and its products,visit AMITIZA® is a registered trademark of Sucampo Pharmaceuticals, Inc Forward-Looking StatementsAny statements in this press release about future expectations, plans andprospects for Sucampo Pharmaceuticals are forward-looking statements made underthe provisions of The Private Securities Litigation Reform Act of 1995.Forward-looking statements may be identified by the words “project,” “believe,”"anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,” “would,”"could,” “will,” “may” or other similar expressions. Actual results may differmaterially from those indicated by such forward-looking statements as a resultof various important factors described in Sucampo Pharmaceuticals` filings withthe Securities and Exchange Commission (SEC), including the annual report onForm 10-K for the year ended December 31, 2007 and other periodic reports filedwith the SEC. Any forward-looking statements in this press release representSucampo Pharmaceuticals` views only as of the date of this release and shouldnot be relied upon as representing its views as of any subsequent date.

SucampoPharmaceuticals anticipates that subsequent events and developments will causeits views to change . However, while Sucampo Pharmaceuticals may elect to updatethese forward-looking statements publicly at some point in the future, SucampoPharmaceuticals specifically disclaims any obligation to do so, whether as aresult of new information, future events or otherwise gold frapp . Sucampo Pharmaceuticals, Inc.Kate de Santis, Copyright Business Wire 2009 black cherry . Ben Roethlisberger may be undertaking the biggest risk of his life by playing on Sunday against the Baltimore Ravens.Big Ben suffered a concussion last Sunday against the Kansas City Chiefs . If Roethlisberger suffers another concussion this weekend he will be at enhanced risk for long-term brain damage.I hope that those around him have adequately explained the long-term risks to his health. I hope that someone has told him about Steelers Legend Mike Webster. Not about how Webster earned four Super Bowl rings protecting Terry Bradshaw and leading the way for Franco Harris.Not about how Webster was so tough that he started in 150 straight games and played in 177 consecutive games.No. The story that needs to be told is what happened after Webster stopped playing.Webster retired from football in March 1991 after playing 16 years and suffering multiple concussions, which had damaged Webster?s frontal lobe.The remaining 11 years of his life after football were not pleasant.Webster?s health deteriorated, leaving him unemployed, debt-ridden, and occasionally homeless.